Go To Global Site
Welcome to UCB in the United States

Feb

25

UCB - Sustaining Growth, Now and Into the Future

Feb

23

UCB and Microsoft Expand Collaboration to Accelerate Drug Discovery and Development

Feb

05

The Lancet Publishes Two Phase 3 Studies Detailing Bimekizumab Data in Moderate to Severe Plaque Psoriasis

Feb

03

UCB Community Health Fund Supports Seven U.S. Organizations on COVID-19 Support Projects

Today, UCB announced seven U.S-based organizations received support from the UCB Community Health Fund managed by the King Baudouin Foundation in Belgium.

Jan

13

Reflecting on Important Lessons from 2020. Looking Towards 2021 with Hope.

2020 tested many long-held beliefs and practices of how we work, how we think about our health, and how we help others. Read more from UCB's Chief Executive Officer & Chairman of the Executive Committee, Jean-Christophe Tellier, as he reflects on the lessons learned and our work to improve the lives of patients now and to create a healthier future.

Jan

12

UCB Announces Launch of Nile AI, Inc., a Digital Health Company Set to Transform the Course of Epilepsy

Dec

15

Spotlight on Boston: UCB’s Investment in a Growing R&D Hub Furthers Our Ability to Deliver Patient Value

While the Boston R&D Hub is relatively young compared to the nearly century-long history of UCB, it represents a continuation and extension of the UCB legacy and our Patient Value Strategy. Read from UCB's Dr. Roger Palframan, Head of External Innovation & U.S. Discovery, on UCB's expanding presence in Boston, Massachusetts and our growing team of talented researchers focused on developing next-generation therapies.

Dec

03

Breaking the Barriers to Better Care: How UCB’s Experience in Epilepsy Is Paving the Way for Transformative Treatments

This week, UCB will present at AES2020, the American Epilepsy Society’s (AES) virtual meeting – one of the largest meetings of researchers, scientists, and advocacy groups in the field – where we are proud to showcase the work we have been doing with and on behalf of the epilepsy community. UCB will showcase 15 scientific posters highlighting the latest research on our epilepsy portfolio and pipeline.

Dec

03

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society’s Virtual Event AES2020

  • 15 scientific presentations highlight data on BRIVACT® (brivaracetam) CV, NAYZILAM® (midazolam) nasal spray CIV, VIMPAT® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
  • UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel

Nov

30

World's Leading Life Science Companies Now Enrolling COMMUNITY, a Global, Platform Trial for Hospitalized Patients with COVID-19